Abstract | BACKGROUND: METHODS: Patients with obesity (BMI, 35-50 kg/m2 ) were enrolled into a 12-week study (N = 88; licogliflozin 150 mg q.d.). Patients with T2DM were enrolled into a second, two-part study, comprising a single-dose cross-over study (N = 12; 2.5 - 300 mg) and a 14-day dosing study (N = 30; 15 mg q.d). Primary endpoints included effects on body weight, effects on glucose, safety and tolerability. Secondary endpoints included urinary glucose excretion (UGE24 ) and pharmacokinetics, while exploratory endpoints assessed the effects on incretin hormones (total GLP-1, PYY3-36 , and GIP), insulin and glucagon. RESULTS: Treatment with licogliflozin 150 mg q.d. for 12 weeks in patients with obesity significantly reduced body weight by 5.7% vs placebo (P < 0.001) and improved metabolic parameters such as significantly reduced postprandial glucose excursion (21%; P < 0.001), reduced insulin levels (80%; P < 0.001) and increased glucagon (59%; P < 0.001). In patients with T2DM, a single dose of licogliflozin 300 mg in the morning prior to an oral glucose tolerance test (OGTT) remarkably reduced glucose excursion by 93% (P < 0.001; incremental AUC0-4h ) and suppressed insulin by 90% (P < 0.01; incremental AUC0-4h ). Treatment with licogliflozin 15 mg q.d. for 14 days reduced 24-hour average glucose levels by 26% (41 mg/dL; P < 0.001) and increased UGE24 to 100 g (P < 0.001) in patients with T2DM. In addition, this treatment regimen significantly increased total GLP-1 by 54% (P < 0.001) and PYY3-36 by 67% (P < 0.05) post OGTT vs placebo, while significantly reducing GIP levels by 53% (P < 0.001). Treatment with licogliflozin was generally safe and well tolerated. Diarrhea (increased numbers of loose stool) was the most common adverse event in all studies (90% with licogliflozin vs 25% with placebo in the 12-week study), while a lower incidence of flatulence, abdominal pain and abdominal distension (25%-43% with licogliflozin vs 9%-11% with placebo in the 12-week study) were among the other gastrointestinal events reported. CONCLUSION:
|
Authors | Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 21
Issue 6
Pg. 1311-1321
(06 2019)
ISSN: 1463-1326 [Electronic] England |
PMID | 30724002
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 John Wiley & Sons Ltd. |
Chemical References |
- Anhydrides
- Blood Glucose
- Sodium-Glucose Transporter 2 Inhibitors
- Sorbitol
- licogliflozin
|
Topics |
- Adult
- Anhydrides
(administration & dosage, adverse effects, pharmacology)
- Blood Glucose
(metabolism)
- Body Weight
(drug effects)
- Cross-Over Studies
- Diabetes Mellitus, Type 2
(blood, complications)
- Female
- Humans
- Male
- Middle Aged
- Obesity
(blood, complications, drug therapy)
- Sodium-Glucose Transporter 2 Inhibitors
(administration & dosage, adverse effects, pharmacology)
- Sorbitol
(administration & dosage, adverse effects, analogs & derivatives, pharmacology)
- Young Adult
|